Incisive Genetics Inc.: federal grants and contributions: 10 agreements; $1.6M value; 1 departments; 4 programs.
Assay record ASY-CA-0SSBLS71Q8 · Cite as: Assay Systems, “Incisive Genetics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/incisive-genetics-inc/
This project will expand the chemistry, manufacturing and controls (CMC) workup of lead formulation materials. This will involve the development of additional quality control measures as well as the expansion of formulation testing and refinement. Additionally, this project aims to demonstrate successful gene editing in the liver.
The project will involve the development of expanded Huntington's Disease gene therapy strategies, addition of retinal and bone marrow targeting capabilities, and demonstration of the delivery of alternate gene editing cargos.
The proposed project will involve repeat dose testing in a Huntington's Disease model to demonstrate the ability to perform titratable genome editing. Additionally the project will involve proof of concept testing in other organ models of genetic disease.
This project will involve determining optimal route of administration of Transfection Competent Vesicle (TCV) delivery of gene editing machinery in vivo efficacy studies to generate critical proof of concept data, advance internal drug development and initiate possible pharma partnering opportunities.
The project will to develop and optimize a process to synthesize and purify the key lipid components for technology transfer of the process to an accredited Good Manufacturing Practice (GMP) facility.
This project will involve the delivery of mRNA and selected guiding gene materials (RNAs) to cells in vitro using Transfection competent vesicle (TCV) to evaluate and determine the suitability of TCVs for bench scale delivery of this genetic cargo.
This project aims to evaluate and determine the effectiveness of a proprietary formulation in the delivery of nucleic acids and gene editing cargo into suspension cell types.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.